Weiss Ratings restated their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report released on Saturday morning,Weiss Ratings reports.
A number of other research firms also recently issued reports on FDMT. Chardan Capital reissued a “buy” rating and set a $39.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Bank of America reduced their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Royal Bank of Canada reduced their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $38.56.
Get Our Latest Stock Analysis on 4D Molecular Therapeutics
4D Molecular Therapeutics Trading Down 2.1 %
Institutional Trading of 4D Molecular Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of 4D Molecular Therapeutics by 10.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company’s stock valued at $14,819,000 after acquiring an additional 65,000 shares during the last quarter. Barclays PLC raised its stake in 4D Molecular Therapeutics by 141.0% during the third quarter. Barclays PLC now owns 114,848 shares of the company’s stock worth $1,241,000 after acquiring an additional 67,202 shares during the period. Novo Holdings A S boosted its position in 4D Molecular Therapeutics by 7.1% during the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after purchasing an additional 100,000 shares during the period. nVerses Capital LLC bought a new stake in 4D Molecular Therapeutics in the third quarter valued at $40,000. Finally, Braidwell LP grew its position in shares of 4D Molecular Therapeutics by 231.7% during the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after acquiring an additional 855,990 shares during the last quarter. 99.27% of the stock is owned by institutional investors.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
- Five stocks we like better than 4D Molecular Therapeutics
- Investing In Preferred Stock vs. Common Stock
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- What is a Death Cross in Stocks?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- 3 Small Caps With Big Return Potential
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.